Mastopon-Treat

Progesterone, the active ingredient in Mastopon-Treat, is a progestogen presented as a vaginal formulation for vaginal use. It supports luteal phase function, helps prevent preterm birth, and is used in hormone replacement therapy.

GNH USA supplies Mastopon-Treat as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Progesterone in Mastopon-Treat acts on the reproductive hormone pathway and is employed in several clinical settings.

- Luteal phase support in assisted reproduction: Enhances endometrial receptivity and supports early pregnancy. - Prevention of preterm birth: Reduces risk of early delivery in at‑risk pregnancies. - Hormone replacement therapy: Provides progestogenic activity to balance estrogen in menopausal women.

Progesterone administered vaginally may be associated with a range of adverse reactions.

Common Side Effects: - Vaginal irritation or burning - Increased vaginal discharge - Spotting or light bleeding - Abdominal cramps or pelvic discomfort - Breast tenderness - Headache

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe allergic reaction (rash, swelling, anaphylaxis) - Significant vaginal bleeding - Hepatic dysfunction (elevated liver enzymes) - Adrenal suppression in prolonged high‑dose use

Use of Mastopon-Treat requires careful clinical assessment and monitoring.

- Contraindications: Do not use in patients with known hypersensitivity to progesterone or any excipients. - Thromboembolic risk: Evaluate history of clotting disorders before initiating therapy. - Liver function: Monitor hepatic enzymes in patients with pre‑existing liver disease. - Dose minimisation: Employ the lowest effective dose for the shortest duration necessary. - Patient education: Instruct patients to report signs of allergic reaction or abnormal bleeding promptly. - Store at room temperature: Keep in the original packaging, protect from moisture and direct sunlight.

Progesterone can interact with several medication classes, influencing efficacy or safety.

Major Interactions (Avoid): - Combined estrogen therapy without progesterone: Increases risk of endometrial hyperplasia. - Anticoagulants (warfarin, direct oral anticoagulants): May enhance bleeding tendency. - Strong CYP3A4 inducers (rifampicin, carbamazepine): Can markedly reduce progesterone levels.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): May increase progesterone concentrations. - Anticonvulsants (phenytoin, phenobarbital): May lower progesterone exposure. - Herbal supplements (St. John’s wort): Potentially decreases progesterone effectiveness.